2seventybio.com (TSVT): Operating Profitability

Public company logo of 2seventy bio Inc. (TSVT)

Growth for 2seventy bio, Inc. (TSVT) is driven by Abecma sales for myeloma therapy and cost optimization. The operating margin on the GURU.Markets chart clearly illustrates profit dynamics, where the value -122.70 captures the current state. High business scalability relies on genetic engineering patents that guarantee margins. An impeccable reputation in oncology confirms physician confidence in innovative treatment methods.

TSVT: 2seventy bio Inc. Operating Return on Sales 07/04/2022 - 05/24/2025

Financial and market metric breakdowns for 2seventy bio, Inc. (TSVT)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company valuation:2seventybio.com, TSVT
Brand item of 2seventy bio, Inc

The efficiency of CAR-T developments and the retention of elite engineers through R&D autonomy directly impact the ability of 2seventy bio (TSVT) to optimize internal costs. This metric reflects the share of operating profit in total revenue, allowing investors to assess the profitability of the core business before accounting for financial obligations and taxes via the operating margin.